Ann: Travelan to progress to Phase 3 Clinical Trials in the US, page-35

Well it is cherrypicking a bit with secondary endpoints - but the antibiotic treatment P value was significant. As this study was underpowered, we seem to be looking at a situation where the extreme cases had a very big difference.
They have dodged a bullet, as if this was ph3 the results would look worse than they are with moderate to severe self reported diarrhea. In this instance the results are statistically significant for antibiotics and nearly SS for an IV.
So these are far less subjective measures that involve a professional doctor or nurse making a decision.

I can't calculate what number of participants is required to get SS on the primary endpoint they used in this trial - but suspect it is far more. A friend who is strong in statistics might provide me with a number.